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Running head: TGFβ signalling as a therapeutic target for RDEB cSCC 
What’s already known about this topic?
 Canonical transforming growth factor beta (TGFβ) signalling is active in RDEB 
patients’ skin and cSCC tumours but its role in tumourigenesis is unknown.
 There is no evidence of mutational inactivation of canonical TGFβ signalling in RDEB 
cSCC.
What does this study add?
 Exogenous TGFβ stimulation of patient derived RDEB cSCC tumour cells (PDTCs) 
activates canonical signalling and inhibits cell proliferation in all samples in vitro.
 Inhibition of endogenous TGFβ signalling inhibits proliferation, clonogenicity, migration 
and invasion in the majority of PDTCs but can also have no effect or promote 
proliferation and clonogenicity in some PDCTs. 
What is the translational message?
 Endogenous TGFβ signalling has potential tumour promoting effects in the majority of 
RDEB cSCCs but may also have tumour supressing effects in some samples.
 TGFβ signalling is an attractive potential therapeutic target in many but not all RDEB 
cSCCs.
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Summary
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is associated with a 
high mortality rate due to the development of life threatening, metastatic cutaneous 
squamous cell carcinoma (cSCC). Elevated transforming growth factor β (TGFβ) 
signalling is implicated in cSCC development and progression in RDEB patients. 
Objective:  To determine the effect of exogenous and endogenous TGFβ signalling in 
RDEB cSCC with a view to assess the potential of targeting TGFβ signalling for RDEB 
cSCC therapy.
Methods: A panel of 11 patient derived RDEB cSCC primary tumour keratinocyte cell 
lines (SCCRDEBs) were tested for their signalling and proliferation responses to 
exogenous TGFβ. Their responses to TGFBR1 kinase inhibitors (SB-431542 and 
AZ12601011(AZA01)) was tested using in vitro proliferation, clonogenicity, migration, 3D 
invasion assays and in vivo tumour xenograft assays. 
Results: All SCCRDEBs respond to exogenous TGFβ by activation of canonical SMAD 
signalling and proliferative arrest. Blocking endogenous signalling by treatment with SB-
431542 and AZ12601011 significantly inhibited proliferation (n=7/11), clonogenicity 
(n=6/11), migration (n=8/11) and invasion (6/11) of SCCRDEBs. However, these 
TGFBR1 kinase inhibitors also promoted proliferation and clonogenicity in 2/11 
SCCRDEBs. Pre-treatment of in vitro TGFBR1 addicted SCCRDEB70 cells with SB-
431542 enhanced overall survival and reduced tumour volume in subcutaneous 
xenografts but had no effect on non-addicted SCCRDEB2 cells in these assays. 
Conclusion: Targeting TGFBR1 kinase activity may have therapeutic benefit in the 
majority of RDEB cSCCs, however, the potential tumour suppressive role of TGFβ 
signalling in a subset of RDEB cSCCs necessitates biomarker identification to enable 
patient stratification before clinical intervention.
Introduction
Epidermolysis bullosa (EB) is a skin fragility disorder caused by mutations in 
genes essential for maintaining the structure and function of the skin. EB has been 
classified into ~30 clinical subtypes 1 including recessive dystrophic epidermolysis bullosa 
(RDEB). RDEB is characterised by mutations in the gene encoding type VII collagen, 
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the epidermis. Mutations in COL7A1 result in either absent or non-functional anchoring 
fibrils causing acute skin blistering and chronic wounding in RDEB patients 4. Symptom 
severity in these patients often results in sepsis and renal failure 5, however, the most 
significant complication in RDEB patients is the onset of aggressive and potentially 
metastatic cutaneous squamous cell carcinomas (cSCC) resulting in a high mortality rate, 
with a cumulative risk of ~90% by age 55 6. The exact mechanisms underlying tumour 
development and rapid progression from primary to metastatic cSCC in RDEB patients is 
unknown. 
Transforming growth factor β (TGFβ) signalling is elevated in RDEB and RDEB 
cSCC derived primary cells and patient tissue7-9. TGFβ is a pleiotropic cytokine that 
signals through a heterotetrameric complex of its receptors TGFBR1 and TGFBR2. 
Canonical TGFβ signalling involves receptor-mediated activation of SMAD transcription 
factors (SMAD2 and SMAD3) that can influence the expression of hundreds of target 
genes. TGFβ can suppress tumourigenesis in epithelial cells by inducing growth arrest 10. 
In contrast, TGFβ can regulate pro-tumourigenic processes such as induction of epithelial 
to mesenchymal transition (EMT) and promotion of migration, invasion and metastasis11-
13. It is unclear whether TGFβ functions as a tumour suppressor or promoter in RDEB 
cSCC disease pathogenesis. Treatment with the angiotensin II type 1 receptor blocker, 
Losartan14, or lentiviral mediated delivery of Decorin15 alleviates RDEB associated 
fibrosis and mitten deformities in COL7A1-hypomorphic mice. The contribution of 
inhibition of TGFβ signalling mediated by these treatments to disease inhibition is unclear 
and the effects of inhibiting TGFβ signalling on chemically induced carcinogenesis in this 
model16 is yet to be explored. Recent studies from our lab indicate that TGFβ acts as a 
potent tumour suppressor in sporadic cSCC where ~30% of cSCCs harbour either 
TGFBR1 or TGFBR2 mutations, leading to the inactivation of canonical signalling 17, and 
mutational alteration in TGFβ signalling 18 and reduction in canonical signalling activity 
correlates with markers of disease progression  17-19. In contrast, mutations in TGFBR1 or 
TGFBR2 have not been found in RDEB cSCC 20, indicative of potential tumour promoting 
canonical TGFβ signalling in these patients. Here, we use a panel of RDEB cSCC patient 
derived keratinocytes (SCCRDEBs) and test their response to exogenous TGFβ 
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in vivo subcutaneous xenografts to shed further light on the therapeutic potential of TGFβ 
signalling inhibitors in RDEB cSCC.
Methods
All patient samples were acquired following informed written consent according to 
the Helsinki guidelines. 
Primary keratinocyte culture
Primary keratinocytes from normal, RDEB and RDEB cSCC patients were 
isolated, validated by STR profiling in house and cultured as previously described21-23. 
COL7A1 mutations were validated in early passage RDEB and RDEB cSCC primary cells 
as previously published20,24. Details of the RDEB cSCC cells used in this study are 
provided in Supplementary Table 1.
Proliferation assays
Cells were treated with either 5ng/ml TGFβ1 (100-21, PeproTech EC Ltd, 
London,UK) or 0.1% BSA/4mM HCL (carrier), or with 10μM TGFBR1 SB-43154225 (1614, 
Tocris, UK) and/or AZA01 (AZ12601011, AstraZeneca)26 or 0.5% DMSO (D2650, Sigma-
Aldrich, UK) as a vehicle control. Proliferation was assessed using the CellTox™ Green 
cytotoxicity assay (G8731, Promega, UK) as previously described22. Cells were imaged 
for 8 to 10 days using the IncuCyte Zoom® live cell imaging system (Essen bioscience). 
Data were analysed using the IncuCyte Zoom® inbuilt software. 
siRNA mediated depletion of TGFBR1
TGFBR1 knock down was achieved using two individual on-target plus siRNAs (J-
003929-09, J-003929-10, Dharmacon-Horizon discovery, UK) and compared to the on-
target plus non-targeting siRNA #1 control (D-001810-01, Dharmacon-Horizon discovery, 
UK). Cells were transfected using lipofectamine® RNAiMAX (13778100, ThermoFisher 
Scientific, UK) according to the manufacturer’s protocol and incubated for 48 hrs prior to 
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The clonogenic potential of primary cells was assessed as previously 
described27,28. Briefly, 3 or 5 cells per well were seeded in a 96 well plate and treated with 
10μM SB-431542/AZA01 or 0.5% DMSO the next day. Cells were incubated for 2 weeks 
to allow colonies to form and stained with 0.4%(w/v) sulforhodamine B (SRB)/1%(v/v) 
acetic acid solution. Colonies containing more than 50 cells as assessed microscopically 
were counted and surviving fractions calculated as previously described27,28. 
Wound heal assays
SCCRDEBs were seeded in a 96 well ImageLock plate (4379, Essen biosciences, 
UK) to achieve a confluent monolayer. The next day, cells were washed and cultured 
overnight in serum starved conditions (0% FBS) to inhibit proliferation (confirmed by 
Incucyte tracking, data not shown). Consistent wounds were inflicted using the wound 
maker (4493, Essen Bioscience, UK), cells were washed in PBS and then  incubated in 
serum free medium with either 10μM SB-431542 or 0.5% DMSO and imaged every 2 hrs  
using the IncuCyte Zoom® until wound closure. Relative wound density was calculated 
using the in-built software. 
Immunoblotting
Protein lysates were prepared in 4X SDS sample buffer and analysed using SDS-
PAGE and western blotting using the following antibodies: PO4-SMAD2 (Ser465/467) 
(3101, Cell Signaling Technology, USA), PO4–SMAD3 (Ser 423/425) (ab52903, Abcam, 
UK),  SMAD2/3 (610842, BD Transduction Laboratories-Europe), SMAD4 (B-8, Santa 
Cruz Biotechnology, UK) and TGFBR1 (V-22, Santa Cruz Biotechnology, UK).  β-actin 
(A2228, Sigma-Aldrich, UK) or GAPDH (G8795, Sigma-Aldrich, UK) were used as the 
loading controls. 
Immunohistochemistry
4μM thick cryosections or formalin fixed paraffin embedded tissue sections were 
stained and imaged as previously described using our published immunohistochemistry 
(IHC) protocol 19 for detecting PO4-SMAD3 (ab52903, Abcam, UK). 
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SCCRDEBs were seeded on a dermal equivalent Matrigel (734-1100, Corning®, 
VWR) – type 1 collagen (C3867, Sigma-Aldrich, UK ) 1:1 gels using a previously 
published protocol 29. Matrigel-collagen1 gels containing fibroblasts were prepared along 
with either 10μM SB-431542 or 0.5% DMSO. SCCRDEBs were seeded on top of the gels 
(with either SB-431542 or DMSO) and incubated overnight. Gels were lifted to air-liquid 
interface and incubated with SB-431542 or DMSO for 7 days before harvesting. Invasion 
indexes were calculated as previously described30. 
Subcutaneous Xenografts
All xenograft work was carried out in the Cancer Research UK Beatson Institute 
with ethical approval from University of Glasgow under the revised Animal (Scientific 
Procedures) Act 1986 and the EU Directive 2010/63/EU (PPL 70/8645).  8 week old 
female SCID mice (Charles River, UK) were injected subcutaneously with the indicated 
number of SCCRDEBs transduced with the lentiviral based imaging vector, BLIV 2.0 
Reporter: CMV-Luciferase-EF1a-copGFP-T2A-Puro (BLIV513PA-1, Systems 
biosciences, CA, USA). In drug treatment experiments, cells were pre-treated with either 
10μM SB-431542 or DMSO for four days prior to injection. 5 mice for SCCRDEB2 and 10 
mice for SCCRDEB70 were used per treatment group. Mice were monitored three times 
weekly by calliper measurements and humanely sacrificed when tumours reached the 
clinical endpoint of ulceration. Tumour volumes were calculated using the formula 
(LxW2)/2 where L= length and W= width.
Statistical analysis
An ordinary two-way analysis of variance (ANOVA) was conducted of end-point 
cell-count assays of TGFβ1, SB-431542, SB-505124 and AZA01 against the appropriate 
vehicle controls. A two-way repeat measures analysis of variance was run on wound heal 
assays to determine the effect of SB-431542 versus the vehicle control on cell migration 
across multiple time points. Three separate experiments of 3D invasion and clonogenicity 
assays were assessed for significance using the student’s t.test with Bonferroni 
correction. Tumour end-point survival was assessed using Kaplan-Meier analysis. 
Adjusted p-values are presented with values considered significant when p < 0.05. 
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Results
TGFβ signalling is active in epidermal skin and primary keratinocytes
We recently reported that TGFβ canonical signalling as measured by PO4-SMAD3 
expression was primarily localised to the hair follicle stem cells in normal skin, is active in 
peri-lesional and cSCC tissue and decreased with markers of disease progression17-19. 
We employed the same method using tissue sections from six RDEB cSCC patients and 
detected nuclear localisation of PO4 –SMAD3 in all RDEB cSCC samples (representative 
samples shown in Figure 1a). PO4-SMAD3 staining was observed in both the dermal and 
epidermal components of the skin with staining also present in the perilesional epidermis.
Treatment with exogenous TGFβ1 showed induction of PO4-SMAD2 and PO4-
SMAD3 in primary keratinocytes isolated from the skin of one normal patient (NHKBr1), 
one RDEB (non-cSCC) patient (RDEB84K) and eleven patient derived SCCRDEBs 
(SCCRDEB2, 3, 4, 53, 62, 70, 71, 99, 106, 108 and 121). These findings confirm that 
canonical TGFβ signalling is intact in all of these epidermal keratinocyte populations 
(Figure 1b, Figure S1). An endogenous level of PO4-SMAD2/3 was also detected 
suggestive of autocrine TGFβ signalling, which was reduced by treatment with the 
TGFBR1 kinase inhibitor, SB-431542.
TGFβ1 can induce growth arrest in epithelial cells during early carcinogenesis 31. 
In line with these previous findings, proliferation of primary keratinocytes isolated from 
normal and non-cSCC RDEB patient skin was significantly inhibited upon treatment with 
exogenous TGFβ1. All SCCRDEBs (n=11/11) were also significantly inhibited in a 
proliferation assay following the addition of exogenous TGFβ1 compared to the vehicle 
control (Figure 2, Figure S2a). Contrary to SCCRDEBs, primary keratinocytes isolated 
from a subset of sporadic cSCCs do not respond to TGFβ1 in a proliferation assay as 
~30% of sporadic cSCCs harbour mutations in TGFBR1 and TGFBR2 genes 17, 
rendering the signalling pathway inactive. Here we show that unlike many sporadic 
cSCCs, all SCCRDEBs maintain an active TGFβ canonical signalling pathway during 
cSCC tumourigenesis and can respond to exogenous cytokine by proliferative arrest 
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SCCRDEBs exhibit heterogeneous proliferation responses to treatment with 
TGFBR1 kinase inhibitors 
Inhibition of endogenous TGFβ signalling using SB-431542 resulted in the promotion of 
proliferation in NHKs and RDEBKs (Figure 3), consistent with the growth inhibition 
observed following treatments with exogenous TGFβ1. However, interestingly, 
proliferation of 63% (n=7/11) of SCCRDEBs (SCCRDEB4, 62, 70, 71, 99, 106 and 108) 
was significantly inhibited upon treatment with SB-431542 (Figure 3, Figure S2a). 
Blocking endogenous signalling significantly promoted proliferation of SCCRDEB2 and 
SCCRDEB121, whereas, SCCRDEB3 and SCCRDEB53 did not respond to SB-431542 
in this assay (Figure 3, Figure S2a). These results were validated using two additional 
TGFBR1 kinase inhibitors AZA01 and SB-505124, in a promoted (SCCRDEB2) and an 
inhibited (SCCRDEB70) cell line in a proliferation assay and kinase inhibition was 
confirmed using immunoblotting as indicated by loss of expression of PO4-SMAD2 
(Figure S2b-c). These data confirm that SCCRDEBs show an inherent heterogeneity in 
response to blocking endogenous TGFβ signalling in a proliferation assay.
SCCRDEBs exhibit heterogeneous clonogenic potential following treatment with 
TGFBR1 kinase inhibitors 
The clonogenic potential of cells is reflective of their stem cell like properties and can be 
measured by assessing the colony forming ability of cancer cells in low-density seeding 
conditions32. SCCRDEBs were seeded at low cell densities and treated with SB-431542 
and AZA01 to assess the effects of blocking TGFβ signalling on colony formation. The 
surviving fraction was calculated following treatment with the inhibitor as previously 
described 27. Six out of 7 of the SCCRDEBs that were inhibited in the proliferation assay 
were also significantly inhibited in the clonogenicity assay following treatment with 
TGFBR1 kinase inhibitors (Figure 4A, Figure S3, Table 2). SCCRDEB71 cells did not 
form colonies. SCCRDEB2 and SCCRDEB121 that were promoted in the proliferation 
assay also showed an enhanced clonogenic potential upon addition of TGFBR1 kinase 
inhibitors (Figure 4a, Table 2); thereby confirming the heterogeneity observed in 
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To confirm the on-target effects of the kinase inhibitors, two individual siRNAs 
were used to deplete the expression levels of TGFBR1 and the clonogenic potential of 
SCCRDEB2,4 and 62 cells was tested following knock down of TGFBR1. Knockdown 
efficiency was assessed by western blotting (Figure 4b). Clonogenicity of SCCRDEB4 
and SCCRDEB62 cells was significantly reduced following knock down using both 
siRNAs targeting TGFBR1 when compared to the non-targeting control (Figure 4b). 
Efficient knockdown of TGFBR1 (with TGFBR1-si10) promoted clonogenicity of 
SCCRDEB2 cells (Figure 4b). These data confirmed that the effect of the TGFBR1 
kinase inhibitors in these cells is on-target.   
SB-431542 inhibits the migration and invasion of TGFBR1 addicted SCCRDEBs 
So far our data indicates that two thirds of the SCCRDEBs are addicted to the 
endogenous kinase activity of TGFBR1 for efficient proliferation and clonogenicity. 
Epithelial cells undergo morphological changes to acquire a pro-migratory and invasive 
phenotype during carcinogenesis and TGFβ can drive migration and invasion of cancer 
cells in a context dependent and tumour cell specific manner10,12,13,33. Consistent with 
this, exogenous TGFβ1 treatment enhanced migration of SCCRDEB2, 4, 71, 99 and 106 
cells, inhibited migration of SCCRDEB53 cells and no effect on migration of  SCCRDEB3, 
62, 70, 108 and 121 cells in a 2D wound heal scratch assay (Figure S4, Table 1). 
Treatment with SB-431542 significantly impaired cell migration of SCCRDEB4, 62, 70, 
99,108 and 121 cells (Figure 5a, Figure S5, Table 2) suggesting a role of endogenous 
TGFβ signalling in promoting a pro-migratory phenotype in these cells. SCCRDEB2, 3 
and 53 cells did not respond to TGFBR1 kinase inhibitors in this assay (Figure S5, Table 
2), providing further evidence of heterogeneity of SCCRDEB responses to TGFBR1 
kinase inhibitors.
Matrigel-type1 collagen gels were used to develop 3D skin equivalents to test the 
invasive potential of SCCRDEBs in the presence of fibroblasts derived from RDEB cSCC 
patients. Invasion assays were carried out either in the presence or absence of SB-
431542 to block endogenous TGFβ signalling and the invasion index was calculated as 
previously described 30. The invasive potential of SCCRDEB4, 62, 70, 99, 106 and 108 
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of the kinase inhibitor in the proliferation, clonogenicity and 2D wound heal assays in the 
same cells. SB-431542 did not inhibit invasion of SCCRDEB71 cells (Figure S6), despite 
inhibiting proliferation and migration of these cells (Table 2). SCCRDEB2 and 
SCCRDEB121 cells which were promoted in proliferation and clonogenicity assays by 
SB-431542 did not show any significant response to SB-431542 in the 3D organotypic 
invasion assay (Figure 5b, Table 2). These data confirm that SCCRDEB2 and 
SCCRDEB121 cells are inherently different to SCCRDEB4/62/70/99/106/108 cells in their 
response to inhibition of TGFBR1 endogenous signalling and that TGFBR1 activity in 
SCCRDEB2, SCCRDEB71 and SCCRDEB121 cells may not play a role in driving 
invasion in these cells.
Targeting TGFBR1 inhibits in vivo tumour growth of SCCRDEB70 but not 
SCCRDEB2 cells.
To determine in vivo tumourigenicity we performed pilot serial dilution subcutaneous 
xenograft experiments using SCCRDEB70, 62, 4 and 2 cells. Consistent tumour growth 
was observed with 4x104-4x106 cells depending on the cell line (Figure S7). H&E staining 
of tumours harvested at the endpoint showed the presence of tumour cells and ulceration 
(Figure S7). SCCRDEB4 cells did not form tumours in this assay. Consistent with our in 
vitro analysis, animals transplanted with SB-431542 pre-treated “TGFBR1 addicted” 
SCCRDEB70 cells showed enhanced survival in in vivo subcutaneous xenografts 
reaching clinical endpoint later when compared to the vehicle control (DMSO) pre-treated 
cells (Figure 6a). Tumour initiation was not affected as 9 out of 10 mice formed tumours 
in the DMSO treated group, whereas, all 10 mice formed tumours in the SB-431542 
treated group. At week 5 tumour volumes of SB-431542 pre-treated xenografts was 
significantly reduced compared to the vehicle control xenografts (Figure 6b). Mice 
injected with SB-431542 pre-treated SCCRDEB2 cells that were promoted in in vitro 
proliferation and clonogenicity assays by this treatment, tended to reach clinical endpoint 
earlier compared to mice injected with DMSO pre-treated cells (Figure S8a), however this 
finding did not reach statistical significance. No significant difference was observed in 
tumour volumes between control or pre-treatment groups (Figure S8b). Overall, our in 
vivo experiments are consistent with our in vitro studies indicating that inhibition of TGFβ 
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Discussion 
Management of life threatening cSCC arising in RDEB patients is challenging with no 
approved treatment options and limb amputation often used as the last resort to combat 
disease progression 34. Radiotherapy and chemotherapy are available as palliative care 
options with little evidence to show any significant impact on overall survival 34. Recent 
work has identified PLK1 as a potential target 35 and ongoing phase II clinical trials with 
rigosertib may provide a much needed opportunity for therapeutic targeting of RDEB 
cSCC. 
Elevated TGFβ signalling has been reported in RDEB skin and postulated as the 
underlying cause for driving inflammation, fibrosis and extracellular matrix remodelling 
and thereby disease severity in RDEB patients 7,14-16. TGFβ has been shown to act as 
both a tumour promoter and suppressor in carcinogenesis in a context dependent 
manner 36. It is unknown whether TGFβ signals as a tumour suppressor or a tumour 
promotor in cSCC development in RDEB patients and therefore if it is an attractive 
therapeutic target for cSCC prevention or treatment. Here we also found TGFβ signalling 
is active in RDEB cSCC tissue and primary keratinocytes confirming previous findings 
(Figure 1a, 1b, S1). Following the validation of intact active canonical TGFβ signalling we 
addressed the question of the potential use of targeting TGFβ signalling for therapeutic 
use in RDEB cSCC patients. We found that exogenous TGFβ treatment inhibited cell 
proliferation in all of the RDEB cSCC cells indicative of a potential tumour suppressor role 
(Summarised in Table1). Maintenance of canonical signalling and potentially tumour 
suppressive anti-proliferative activity in all RDEB samples studies is in stark contrast to 
our findings in sporadic cSCC, where, mutational inactivation of canonical TGFβ 
signalling occurs in ~30% of tumours which results in loss of anti-proliferative tumour 
suppressive effects17. This finding indicates that loss of tumour suppressive TGFβ 
signalling is not required for cSCC development in RDEB patients and that TGFβ 
signalling may act as a tumour promoter.
 Despite the universal anti-proliferative response of SCCRDEBs to exogenous 
TGFβ we surprisingly observed heterogeneous responses to blockade of endogenous 
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approaches in a range of in vitro assays (summarised in Table 2), which were validated 
in vivo (Figure 6). TGFβ signalling can act as a potential tumour promoter in 
approximately two thirds of patient derived SCCRDEBs as inhibition of endogenous 
signalling blocks proliferation, migration and invasion in vitro (Table 2) and tumour growth 
in vivo, suggesting that targeting this pathway may be of significant therapeutic value to 
patients harbouring these tumours. Importantly, however, we also found that inhibiting 
endogenous signalling had no effect in 2/11 cell lines and promoted proliferation and 
clonogenicity in a further 2 indicating that inhibiting TGFβ signalling in these patients may 
have no clinical benefit or even promote disease progression. 
Immunoblotting of SCCRDEBs show no obvious evidence of difference in basal or 
induced level of TGFβ canonical signalling in the TGFBR1 addicted vs. non-addicted 
cells as assessed by PO4-SMAD2/3 expression (Figure 1b and S1),  making it difficult to 
explain the heterogeneity in TGFBR1 inhibition responses of SCCRDEBs based on 
autocrine TGFβ signalling. Analysis of the publically available whole exome sequencing 
dataset 20 for the  SCCRDEBs (SCCRDEB4 and 121 data not available) we found 
SCCRDEBs that are not addicted to TGFBR1 activity (SCCRDEB2, 3 and 53) harbour 
mutations in FAT1, whereas,  TGFBR1 ‘addicted’ lines are FAT1 wild type (SCCRDEB 
62, 70,71,99,106 and 108) (Figure S9). Somatic mutations in FAT1 are frequently 
reported in cancer 37,38 including sporadic cSCC 18. Functional FAT1 can suppress Wnt/β-
catenin signalling, in turn inhibiting proliferation of cancer cells by blocking cell cycle 
progression at the G1-S checkpoint 38. Loss of function mutation in FAT1 is associated 
with cancer progression and is shown to result in drug resistance via downregulation of 
the Hippo signalling pathway in breast cancer 39. Whether treatment with SB-431542 in 
FAT1 wild type SCCRDEBs results in dysregulation of the hippo and or Wnt/β-catenin 
signalling still remains to be tested. Additionally, the role of non-canonical signalling 
pathways (PI3K/AKT, MAPK etc) and other members of the TGFβ superfamily (including 
Activins and BMPs, their receptors and downstream SMADs) in determining 
heterogeneous TGFBR1 addiction needs to be explored to achieve a better 
understanding of the molecular mechanisms underlying the heterogeneous response to 
TGFβ signalling inhibition in RDEB cSCC and ensure an informed biomarker driven 
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that clinical trials using agents with anti-TGFβ signalling activity in RDEB and RDEB 
cSCC should proceed with caution due to the potential tumour suppressive function of 
the canonical TGFβ signalling pathway in some RDEB cSCCs. 
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Figure legends
Figure 1: TGFβ signalling is active in RDEB cSCC tissue and cells
a. Representative images of immunohistochemical analysis of RDEB cSCC patient tissue 
indicates heterogeneous nuclear localisation of PO4-SMAD3 (red arrows) in both tumour cells and 
in the dermal (D) and epidermal (E) components of the skin (perilesional skin Patient1). Scale bar 
= 100μM. b. Western blotting analysis indicates that PO4-SMAD2/3 is induced following treatment 
with TGFβ1 (5ng/ml, 2 hrs) in patient derived NHK (NHKBr1), RDEBK (RDEB84K) and RDEB 
cSCCKs (SCCRDEB2,3,4,53,62 and 70) and that this is blocked by co-treatment with the 
TGFBR1 kinase inhibitor SB-431542.Total SMAD2/3 and SMAD4 is detectable in all primary 
keratinocytes tested. Beta-Actin is used as a loading control.
Figure 2: Exogenous TGFβ inhibits proliferation of primary normal and tumour 
derived keratinocytes
Cell proliferation asssays were performed using the IncuCyte ZOOM® live cell imaging 
system and the CellTox™ Green cytotoxicity assay (n=3). Exogenous TGFβ1 (5ng/ml) 
inhibits proliferation of NHK (NHKBr1/Br2), RDEBK (RDEB84K) and SCCRDEBs (SCCRDEB2, 
3, 4, 53, 62 and 70) compared to the vehicle control. Endpoint two-way ANOVA, error 
bars= 95% CI, **** = p<0.0001.
Figure 3: SB-431542 promotes proliferation in normal keratinocytes and inhibits or 
promotes proliferation of a subset of SCCRDEBs
Proliferation was assessed using the IncuCyte ZOOM® live cell imaging system and the 
CellTox™ Green assay. Patient derived normal human keratinocytes (NHKBr1/Br2), 
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SB-431542 (10μM) or DMSO (vehicle control). Proliferation of normal keratinocytes and 
SCCREDB2 cells was promoted whereas proliferation of SCCRDEBs (SCCRDEB4, 62 
and 70) was inhibited. End point two-way ANOVA, N=3, error bars= 95% CI, p<0.0001.
Figure 4: TGFBR1 kinase inhibitors inhibit or promote clonogenic potential of a 
subset of SCCRDEBs 
a. SCCRDEBs were seeded (3 cells/well in middle 60 wells of a 96 well plate) and treated 
with either DMSO, SB-431542 (10μM) or AZA01 (10μM). Clonogenic potential was 
assessed 2 weeks post treatment following staining with sulforhodamine B. Upper panels 
show representative images and lower graphs indicate quantification of surviving 
fractions, N=3 error bars= 95% CI, two tailed student T-test with corrected p-values 
according to Bonfferoni principles *=p<0.05, **=p<0.01, ***p=<0.001. The clonogenic 
potential of SCCRDEB4, 62 and 70 was inhibited whereas it was promoted in 
SCCRDEB2 and 121 following treatments with SB-431542 and AZA01. b. Two siRNAs 
targeting TGFBR1 (TGFBR1 si9/si10) also enhanced the clonogenic potential in 
SCCRDEB2 cells and inhibited clonogenicity of SCCRDEB4 and SCCRDEB62 compared 
to the non-targeting control siRNA. Representative images shown in upper left panels 
and surviving fraction quantification is shown in the lower graphs. N=3, error bars= 95% 
CI. Two tailed student T-test with adjusted p-values according to Bonfferoni principles. 
*p<0.05. **p<0.01, ***p<0.001. Right hand panels show Western blot analysis confirming 
loss of expression of TGFBR1 following knockdown using both (Si9 and Si10) TGFBRI 
siRNAs in all cells. Beta-Actin was used as a loading control.
Figure 5: SB-431542 can inhibit the pro-migratory and pro-invasive phenotype of 
TGFBR1 addicted SCCRDEBs
a. Real time wound heal-scratch InCucyte Zoom® live cell imaging analysis.  SB-431542 
(10μM) can inhibit migration of SCCRDEB4, 62 and 70 cells compared to the vehicle 
control (DMSO). Two-way repeat measures ANOVA, N=3 biological replicates, error 
bars= 95% CI, ****= p<0.001. b. The invasive potential of a panel of SCCRDEBs was 
assessed using Matrigel-Collagen 1 gels (1:1). RDEB cSCC fibroblasts (SCCRDEB71F) 
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collagen dermal equivalents. SB-431542 treatment inhibited the invasive potential of 
SCCRDEB4, 62 and 70 cells and did not effect this in SCCRDEB2 and SCCRDEB121 
cells. Representative H and E images are shown in the upper panels with examples of 
invading keratinocyte colonies marked with black arrows. Lower graphs show 
quantification of invasion indexes. N=3 independent experiments, mean±SD. Two tailed 
student t-test **p<0.01 and * p<0.05, Scale bar = 100μM
Figure 6: Pre-treatment of SCCRDEB70 cells with SB-431542 extends survival and 
delays tumour growth in a xenograft assay 
a. Overall survival of mice subcutaneously injected with SB-431542 (n=10) or DMSO 
(n=9) pre-treated SCCRDEB70 cells as determined by Kaplan-Meier analysis. The 
curves show an enhanced survival of mice injected with SB-431542 pre-treated 
SCCRDEB70 cells compared to the DMSO pre-treated cells (p=0.01). b. Calliper 
measured tumour volume at 5 weeks post injection of SB-431542 pre-treated xenografts 
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Cells PO4-SMAD2 PO4-SMAD3 Proliferation 2D-Migration
SCCRDEB2 induced induced inhibited promoted
SCCRDEB3 induced induced inhibited no effect
SCCRDEB4 induced induced inhibited promoted
SCCRDEB53 induced induced inhibited inhibited
SCCRDEB62 induced induced inhibited no effect
SCCRDEB70 induced induced inhibited no effect
SCCRDEB71 induced induced inhibited promoted
SCCRDEB99 induced induced inhibited promoted
SCCRDEB106 induced induced inhibited promoted
SCCRDEB108 induced induced inhibited no effect
SCCRDEB121 induced induced inhibited no effect
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Cells Proliferation Clonogenicity 2D-Migration 3D-Invasion
SCCRDEB2 promoted promoted no effect no effect
SCCRDEB3 no effect no effect no effect no effect
SCCRDEB4 inhibited inhibited inhibited inhibited
SCCRDEB53 no effect no effect no effect no effect
SCCRDEB62 inhibited inhibited inhibited inhibited
SCCRDEB70 inhibited inhibited inhibited inhibited
SCCRDEB71 inhibited no colonies inhibited no effect
SCCRDEB99 inhibited inhibited inhibited inhibited
SCCRDEB106 inhibited inhibited inhibited inhibited
SCCRDEB108 inhibited inhibited inhibited inhibited
SCCRDEB121 promoted promoted inhibited no effect
Table 2: Summary of responses of SCCREDEB cells to inhibition of endogenous TGFβ1 
signalling. 
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